Neoadjuvant and adjuvant therapy of non-small cell lung cancer

Lakshmi Rajdev, Steven M. Keller

Research output: Contribution to journalReview articlepeer-review

19 Scopus citations


Though surgery offers the best chance of cure for patients with non-small cell lung cancer (NSCLC), many patients who undergo complete tumor resection will die of recurrent disease. Chemotherapy and radiotherapy have been employed both individually and in combination in an effort to prevent local recurrence and extrathoracic metastatic disease. However, the administration of neoadjuvant or adjuvant therapy remains controversial. Phase II and III trials with traditional radiotherapy schedules and cytotoxic drugs have produced conflicting results. Novel approaches utilizing long-term administration of less toxic drugs and targeted biologic therapies are promising.

Original languageEnglish (US)
Pages (from-to)243-253
Number of pages11
JournalSurgical Oncology
Issue number4
StatePublished - Dec 2002


  • Adjuvant therapy
  • Clinical trials
  • Neoadjuvant therapy
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Surgery
  • Oncology


Dive into the research topics of 'Neoadjuvant and adjuvant therapy of non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this